Biosimilar Gene Therapy: Investigational Assessment ofSecukinumab Gene Therapy

摘要

Tumor necrosis factor-alpha (TNF-α), checkpoint inhibitors, and interleukin-17 (IL-17) are critical targets ininflammation and autoimmune diseases. Monoclonal antibodies (mAbs) have a successful portfolio in the treatment of chronicdiseases. With the current progress in stem cells and gene therapy technologies, there is the promise of replacing costly mAbsproduction in bioreactors with a more direct and cost-effective production method inside the patient’s cells. In this paper weexamine the results of an investigational assessment of secukinumab gene therapy.